[153Sm-EDTMP in the treatment of bone metastasis of lung cancer].
To explore the clinical effect of 153Sm-EDTMP therapy in the treatment of bone metastasis of lung cancer. One hundred and ten patients with painful bone metastasis were entered into this study. The patients were administrated with two steps. At first , they were injected with tracer dose of 153Sm-EDTMP. After a series of index were calculated , such as urine discharge , bone uptake , cumulated skeletal activity , absorbed dose of red marrow and total dose , the second injection was given. Of 110 cases , 98 (89. 1 %) experienced pain relief with complete response in 38 cases and partial response in 60 ones. Pain relief occurred from 3 h to 4 weeks (7. 5 d +/-6. 3 d) . Duration of pain relief from single injection ranged from 2 to 4 weeks. Follow-up imaging studies were performed within 3 months. In 12 cases , metastatic foci disappeared completely (CR) , Karnofsky score increased by 20 , and analgesic were discontinued. In 20 patients , both number and diameter of metastatic foci decreased (PR) , with an improvement in Karnofsky score ranging from 10 to 15. There were significant decreases in WBC and platelet count found in 35 of 110 patients after therapy , however , blood cell counts returned to baseline within 1 to 3 months. 153Sm-EDTMP has proven to be a safe and effective therapy for bone pain in lung cancer , and often results in shrinkage or disappearance of metastatic foci.